174 related articles for article (PubMed ID: 25618124)
1. Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report.
Usnarska-Zubkiewicz L; Strutyńska-Karpińska M; Zubkiewicz-Kucharska A; Zarębski P; Grabowski K
Adv Clin Exp Med; 2014; 23(6):959-67. PubMed ID: 25618124
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
4. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
[TBL] [Abstract][Full Text] [Related]
5. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
6. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
8. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
[TBL] [Abstract][Full Text] [Related]
10. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.
Zimmermann HW; Reuken PA; Koch A; Bartneck M; Adams DH; Trautwein C; Stallmach A; Tacke F; Bruns T
J Intern Med; 2013 Jul; 274(1):86-100. PubMed ID: 23432143
[TBL] [Abstract][Full Text] [Related]
11. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
12. The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer.
Wach S; Al-Janabi O; Weigelt K; Fischer K; Greither T; Marcou M; Theil G; Nolte E; Holzhausen HJ; Stöhr R; Huppert V; Hartmann A; Fornara P; Wullich B; Taubert H
Int J Cancer; 2015 Sep; 137(6):1406-16. PubMed ID: 25754273
[TBL] [Abstract][Full Text] [Related]
13. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
[TBL] [Abstract][Full Text] [Related]
14. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
Riisbro R; Christensen IJ; Piironen T; Greenall M; Larsen B; Stephens RW; Han C; Høyer-Hansen G; Smith K; Brünner N; Harris AL
Clin Cancer Res; 2002 May; 8(5):1132-41. PubMed ID: 12006529
[TBL] [Abstract][Full Text] [Related]
16. Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma.
Chounta A; Ellinas C; Tzanetakou V; Pliarhopoulou F; Mplani V; Oikonomou A; Leventogiannis K; Giamarellos-Bourboulis EJ
Liver Int; 2015 Feb; 35(2):601-7. PubMed ID: 25348952
[TBL] [Abstract][Full Text] [Related]
17. The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia.
Erkut N; Menteşe A; Özbaş HM; Ermantaş N; Sümer A; Örem A; Sönmez M
Turk J Haematol; 2016 Jun; 33(2):135-40. PubMed ID: 26376588
[TBL] [Abstract][Full Text] [Related]
18. [Dynamic changes in plasma levels of urokinase type plasminogen activator and urokinase type plasminogen activator receptor in patients with systemic inflammatory response syndrome].
Wu XL; Yu L; Long D; Yang JH; Zhang YC; Geng F
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2011 Aug; 23(8):478-81. PubMed ID: 21878172
[TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
[TBL] [Abstract][Full Text] [Related]
20. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
Riisbro R; Christensen IJ; Nielsen HJ; Brünner N; Nilbert M; Fernebro E
Int J Biol Markers; 2005; 20(2):93-102. PubMed ID: 16011039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
